Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

August 31, 2022

Conditions
InfluenzaVaccine ReactionDiabetes MellitusChronic Kidney Diseases
Interventions
DRUG

Trivalent Influenza Vaccine

We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.

Trial Locations (1)

Unknown

AMC Hospital, Bandung

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biofarma

INDUSTRY

collaborator

Universiti Sains Malaysia

OTHER

lead

Universitas Padjadjaran

OTHER

NCT06252051 - Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD) | Biotech Hunter | Biotech Hunter